158 related articles for article (PubMed ID: 21045090)
1. Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker.
Holtzman DM
JAMA; 2010 Nov; 304(17):1887. PubMed ID: 21045090
[No Abstract] [Full Text] [Related]
2. Biomarkers for the early diagnosis of Alzheimer's disease.
de Leon MJ; Klunk W
Lancet Neurol; 2006 Mar; 5(3):198-9. PubMed ID: 16488371
[No Abstract] [Full Text] [Related]
3. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
Dean RA; Shaw LM
Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
[No Abstract] [Full Text] [Related]
4. Advances on biological markers in early diagnosis of Alzheimer disease.
Padovani A; Borroni B; Di Luca M
Adv Clin Chem; 2005; 39():107-29. PubMed ID: 16013669
[No Abstract] [Full Text] [Related]
5. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
[No Abstract] [Full Text] [Related]
6. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
7. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
8. Sharpen that needle.
Herskovits AZ; Growdon JH
Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
[No Abstract] [Full Text] [Related]
9. Will CSF analysis become routine in people with memory complaints?
Gauthier S
Lancet Neurol; 2009 Jul; 8(7):595-6. PubMed ID: 19523878
[No Abstract] [Full Text] [Related]
10. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers for prognosis of long-term cognitive treatment outcomes in patients with idiopathic normal pressure hydrocephalus.
Nakajima M; Miyajima M; Ogino I; Akiba C; Sugano H; Hara T; Fusegi K; Karagiozov K; Arai H
J Neurol Sci; 2015 Oct; 357(1-2):88-95. PubMed ID: 26169158
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
Ivanoiu A; Sindic CJ
Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.
Perret-Liaudet A; Pelpel M; Tholance Y; Dumont B; Vanderstichele H; Zorzi W; ElMoualij B; Schraen S; Moreaud O; Gabelle A; Thouvenot E; Thomas-Anterion C; Touchon J; Krolak-Salmon P; Kovacs GG; Coudreuse A; Quadrio I; Lehmann S
Clin Chem; 2012 Apr; 58(4):787-9. PubMed ID: 22322825
[No Abstract] [Full Text] [Related]
14. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
15. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
16. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
[TBL] [Abstract][Full Text] [Related]
17. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
20. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
Zetterberg H; Andreasen N; Blennow K
Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
